ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: () Report Updated: Apr 14, 2014 | Print This Page

Get more stock ratings by Louis Navellier

(PBTH)

Rating: Volatility:
Total Grade: Industry:
Competitors:

Stock Analysis

Rating: Monthly View

A
B
C
D
F
April May June July August September October November December January February March

Rating: Weekly View

This Week: down no change
Last Week: same no change
Two Weeks Ago: up no change
service keys

© quotemedia

Company Profile

PROLOR Biotech, Inc., a development stage biopharmaceutical company, engages in the development of proprietary versions of already-approved therapeutic proteins. Its technology, Carboxyl Terminal Peptide technology could be attached to an array of existing therapeutic proteins, stabilizing the therapeutic protein in the bloodstream and extending its life span without additional toxicity or loss of desired biological activity. The company’s products under development include Human Growth Hormone for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; and Factor IX to Hemophilia B patients for blood clotting under the BeneFIX brand name. Its products under development also comprise Anti-Obesity Peptide Oxyntomodulin; Factor VIIa; Interferon β and Erythropoietin; and Atherosclerosis and rheumatoid arthritis long-acting therapies. The company was formerly known as Modigene Inc. and changed its name to PROLOR Biotech, Inc. in June 2009. PROLOR Biotech, Inc. is based in Nes Ziona, Israel.

Recent News: